Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Revenue (2021 - 2025)

Valion Bio has reported Revenue over the past 5 years, most recently at $146000.0 for Q3 2025.

  • For Q3 2025, Revenue rose 15.87% year-over-year to $146000.0; the TTM value through Sep 2025 reached $482000.0, down 49.63%, while the annual FY2024 figure was $780000.0, 33.67% down from the prior year.
  • Revenue for Q3 2025 was $146000.0 at Valion Bio, up from $86000.0 in the prior quarter.
  • Over five years, Revenue peaked at $528000.0 in Q2 2022 and troughed at $70000.0 in Q1 2025.
  • A 5-year average of $281894.7 and a median of $282000.0 in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: surged 97.01% in 2022 and later crashed 79.04% in 2025.
  • Year by year, Revenue stood at $389000.0 in 2021, then increased by 4.88% to $408000.0 in 2022, then dropped by 12.5% to $357000.0 in 2023, then tumbled by 49.58% to $180000.0 in 2024, then decreased by 18.89% to $146000.0 in 2025.
  • Business Quant data shows Revenue for TIVC at $146000.0 in Q3 2025, $86000.0 in Q2 2025, and $70000.0 in Q1 2025.